Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference
Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference Seattle, WA -- (May 28, 2019) Kineta, Inc., a clinical stage biotechnology company focused on the develop ...
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up t ...
Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever
Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever Phase 1 study to assess the safety, tolerability and pharmacokinetic profile of LHF-535 in healthy volunteers ...